Delving into the Latest Updates on LNP-3794 with Synapse

This is a study in adults with advanced cancer (solid tumours including non-small cell lung cancer and colorectal cancer) in whom previous chemotherapy was not successful. People who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes cancer grow faster.
The study tests 2 medicines called BI 1701963 and BI 3011441. BI 1701963 and BI 3011441 prevent activation of KRAS.
The purpose of this study is to find out the highest dose of BI 1701963 alone and in combination with BI 3011441 the participants can tolerate. Another purpose is to check whether BI 1701963 in combination with BI 3011441 is able to make tumours shrink.
Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they get tablets of BI 1701963 and capsules of BI 3011441 once daily. The doctors regularly monitor the size of the tumour. Doctors also regularly record any unwanted effects and check participants' health.

Start Date20 Apr 2021

Sponsor / Collaborator

Boehringer Ingelheim GmbH

JPRN-jRCT2031200249

/ Not yet recruitingPhase 1IIT

A phase I open-label trial of BI 3011441 in Japanese patients with NRAS/KRAS mutation positive advanced, unresectable or metastatic refractory solid tumours

Start Date26 Mar 2021

Sponsor / Collaborator-

NCT04742556

/ CompletedPhase 1

A Phase I Open-label Trial of BI 3011441 in Japanese Patients With NRAS/KRAS Mutation Positive Advanced, Unresectable or Metastatic Refractory Solid Tumours

This study is open to Japanese adults with different types of advanced cancer that are positive for NRAS/KRAS mutations. This is a study in people for whom previous treatment was not successful or no standard treatment exists.
The purpose of this study is to find the highest dose of BI 3011441 that Japanese people with advanced cancer can tolerate. BI 3011441 is a medicine that may turn off a signal by NRAS/KRAS that makes tumours grow.
Participants take BI 3011441 as capsules once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors collect information on any health problems of the participants.

Start Date15 Mar 2021

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with LNP-3794

Login to view more data

100 Translational Medicine associated with LNP-3794

Login to view more data

100 Patents (Medical) associated with LNP-3794

Login to view more data

1

News (Medical) associated with LNP-3794

26 May 2021

·www.pharmaindustrial-india.com

Lupin announces achievement of key milestones for its clinical stage MEK inhibitor compound

Global pharma major Lupin Limited announced the achievement of key milestones for Lupin’s MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers. As part of the agreement, Lupin has received payment of US$ 50 million from Boehringer Ingelheim for achievement of key milestones. Lupin and Boehringer Ingelheim inked a licensing, development and commercialization agreement in 2019 for Lupin’s novel oncology compound to treat KRAS-driven cancers. Lupin’s MEK inhibitor developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination. Lupin’s New Chemical Entity Research team is focused on building a pipeline of highly differentiated and innovative new chemical entities, primarily in the oncology space. Lupin’s NCE activities were started with the vision to use cutting-edge research in bringing novel molecules that address unmet medical needs in multiple therapeutic areas to market globally.

License out/in

100 Deals associated with LNP-3794

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 3	India	Lupin Ltd	15 Dec 2017
Advanced cancer	Phase 1	Japan	Boehringer Ingelheim GmbH	15 Mar 2021
KRAS G12D mutation Solid Tumors	Phase 1	Japan	Boehringer Ingelheim GmbH	15 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	Belgium	Lupin Ltd	22 Sep 2020
Advanced Malignant Solid Neoplasm	Phase 1	Netherlands	Lupin Ltd	22 Sep 2020
Advanced Malignant Solid Neoplasm	Phase 1	United Kingdom	Lupin Ltd	22 Sep 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04742556 (CTgov)	Phase 1	KRAS G12D mutation Solid Tumors \| Advanced cancer	15	BI 3011441 (4 mg BI 3011441)	ndzxrqdjvn = bazkzynqon hcmoqwvehk (yyifwgnbtn, yvovdbhkzq - veunmnaaur) View more	-	19 Sep 2024
				BI 3011441 (8 mg BI 3011441)	ndzxrqdjvn = kuegvgtqjo hcmoqwvehk (yyifwgnbtn, qsqhvtasqn - pfvhgnmdrx) View more